Amgen Bolsters its CV Pipeline with Arrowhead’s RNA Interference Therapies

By Jasmine Kalsi

Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)

Published: 19 Oct-2016

DOI: 10.3833/pdr.v2016.i10.2202     ISSN: 1756-7874

Section: Licensing



In a bid to build its cardiovascular pipeline, Amgen has entered into two agreements with Arrowhead Pharmaceuticals to develop and commercialise RNA interference (RNAi) therapies for cardiovascular disease...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details